JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
Hong Kong
· Delayed Price · Currency is HKD 1.580
+0.050 (3.27%)
May 2, 2025, 4:08 PM HKT
HKG:2126 Revenue
In the year 2024, JW (Cayman) Therapeutics Co. had annual revenue of 158.22M CNY, down -8.99%. JW (Cayman) Therapeutics Co. had revenue of 71.40M in the half year ending December 31, 2024, a decrease of -10.40%.
Revenue
158.22M CNY
Revenue Growth
-8.99%
P/S Ratio
3.80
Revenue / Employee
563.05K CNY
Employees
281
Market Cap
640.33M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Alibaba Health Information Technology | 31.39B |
| Akeso | 2.26B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |